Status:
UNKNOWN
The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients
Lead Sponsor:
HaEmek Medical Center, Israel
Conditions:
Atherosclerosis
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
Diabetes is a highly atherogenic disease. Pomegranate juice has impressive antioxidant properties. It has been proven to decrease oxidant stress and to cause the regression of atherosclerotic plaques ...
Eligibility Criteria
Inclusion
- Males
- HBA1C\>7%
- Drug therapy given for DM
Exclusion
- Age\<18
- Inclusion in another study
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
End Date :
August 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00470808
Start Date
May 1 2007
End Date
August 1 2007
Last Update
May 8 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ha'Emek Medical Center
Afula, Israel, 18101